JNJ says new data buoys TAR-200 monotherapy for bladder cancer

Posted on by wpadmin
Urinary bladder cancer with organs and tumors or cancerous cells 3D rendering illustration with male body. Anatomy, oncology, biomedical, disease, medical, biology, science, healthcare concepts.

libre de droit

  • Johnson & Johnson (NYSE:JNJ) said that new data it is set to present at the American Urological Association 2025 Annual Meeting later this month strengthens the case for TAR-200 as a monotherapy for bladder cancer.
  • The results are from the

Leave a Reply

Your email address will not be published. Required fields are marked *